MEK/Erk and PI3K/Akt could also be activated by different growth factors, such as EGFR and ErbB3 [45–47], thus tumor types and stages, as well as CD44 isoforms and expression levels should be considered when these inhibitors are combined with chemotherapy for PDAC treatment. This evidence concerns the gene CD44 and neoplasm.